Carlos Vilches
Research Subjects
Research Interests
Carlos Vilches has a total of 538 co-authors. Here are the top co-authors by number of shared publications:
- Miguel López-Botet
University Pompeu Fabra 1 Department of Medicine and Life Sciences Barcelona, Spain
24 shared publications - Aura Muntasell
Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
17 shared publications Manuela Moraru
Immunogenetics & Histocompatibility Lab Instituto de Investigación Sanitaria Puerta de Hierro – Segovia de Arana Majadahonda Spain
16 shared publicationsR. de Pablo
Laboratorio de Inmunogenética‐HLA Hospital Universitario Puerta de Hierro Madrid Spain
14 shared publicationsM. Kreisler
Servicio de Inmunología, Clínica Puerta de Hierro, Madrid, Spain
13 shared publicationsRosario de Pablo
Department of Immunology, Hospital Universitario Puerta de Hierro, Madrid, Spain
13 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The CD94/NKG2A–HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective
Summary of selected clinical trials assessing the safety/clinical efficacy of targeting NKG2A
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The CD94/NKG2A–HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective
Summary of selected clinical trials assessing the safety/clinical efficacy of targeting NKG2A
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Data from The CD94/NKG2A–HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective
Successful clinical development of PD-1/PD-L1 and CTLA4 immune checkpoint blockers intensified the search for other potential targets for cancer immunotherapy. Among them, the CD94/NKG2A inhibitory receptor displayed by NK cell and T-cell subsets, which specifically interacts with the nonclassic HLA-E class I molecule, has attracted special attention. Here, we provide an overview of basic concepts on the CD94/NKG2A–HLA-E axis biology relevant in the framework of ongoing cancer immunotherapy approaches in different scenarios. First, the effectiveness of blocking the NKG2A–HLA-E interaction in vitro and in preclinical models as well as the presence of infiltrating NKG2A+ CD8+ T cells in some solid tumors has led to the generation of clinical-grade NKG2A-specific monoclonal antibodies, pioneered by monalizumab, currently tested in clinical trials. Second, controlling NKG2A expression by genetic engineering constitutes a promising approach to improve advanced adoptive NK cell–based immunotherapies. Challenges include identifying predictive biomarkers of responsiveness, selecting appropriate clinical settings, and optimizing combinatorial regimens.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The CD94/NKG2A–HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective
Successful clinical development of PD-1/PD-L1 and CTLA4 immune checkpoint blockers intensified the search for other potential targets for cancer immunotherapy. Among them, the CD94/NKG2A inhibitory receptor displayed by NK cell and T-cell subsets, which specifically interacts with the nonclassic HLA-E class I molecule, has attracted special attention. Here, we provide an overview of basic concepts on the CD94/NKG2A–HLA-E axis biology relevant in the framework of ongoing cancer immunotherapy approaches in different scenarios. First, the effectiveness of blocking the NKG2A–HLA-E interaction in vitro and in preclinical models as well as the presence of infiltrating NKG2A+ CD8+ T cells in some solid tumors has led to the generation of clinical-grade NKG2A-specific monoclonal antibodies, pioneered by monalizumab, currently tested in clinical trials. Second, controlling NKG2A expression by genetic engineering constitutes a promising approach to improve advanced adoptive NK cell–based immunotherapies. Challenges include identifying predictive biomarkers of responsiveness, selecting appropriate clinical settings, and optimizing combinatorial regimens.
- Open Access
- 7 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1013-1019
The CD94/NKG2A–HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective
Successful clinical development of PD-1/PD-L1 and CTLA4 immune checkpoint blockers intensified the search for other potential targets for cancer immunotherapy. Among them, the CD94/NKG2A inhibitory receptor displayed by NK cell and T-cell subsets, which specifically interacts with the nonclassic HLA-E class I molecule, has attracted special attention. Here, we provide an overview of basic concepts on the CD94/NKG2A–HLA-E axis biology relevant in the framework of ongoing cancer immunotherapy approaches in different scenarios. First, the effectiveness of blocking the NKG2A–HLA-E interaction in vitro and in preclinical models as well as the presence of infiltrating NKG2A+ CD8+ T cells in some solid tumors has led to the generation of clinical-grade NKG2A-specific monoclonal antibodies, pioneered by monalizumab, currently tested in clinical trials. Second, controlling NKG2A expression by genetic engineering constitutes a promising approach to improve advanced adoptive NK cell–based immunotherapies. Challenges include identifying predictive biomarkers of responsiveness, selecting appropriate clinical settings, and optimizing combinatorial regimens.
- 7 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1013-1019
Open AccessThe CD94/NKG2A–HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective
Successful clinical development of PD-1/PD-L1 and CTLA4 immune checkpoint blockers intensified the search for other potential targets for cancer immunotherapy. Among them, the CD94/NKG2A inhibitory receptor displayed by NK cell and T-cell subsets, which specifically interacts with the nonclassic HLA-E class I molecule, has attracted special attention. Here, we provide an overview of basic concepts on the CD94/NKG2A–HLA-E axis biology relevant in the framework of ongoing cancer immunotherapy approaches in different scenarios. First, the effectiveness of blocking the NKG2A–HLA-E interaction in vitro and in preclinical models as well as the presence of infiltrating NKG2A+ CD8+ T cells in some solid tumors has led to the generation of clinical-grade NKG2A-specific monoclonal antibodies, pioneered by monalizumab, currently tested in clinical trials. Second, controlling NKG2A expression by genetic engineering constitutes a promising approach to improve advanced adoptive NK cell–based immunotherapies. Challenges include identifying predictive biomarkers of responsiveness, selecting appropriate clinical settings, and optimizing combinatorial regimens.
Hemizygous Amplification and Sanger Sequencing of HLA‐B*35:433 From an Umbilical‐Cord Blood Sample
HLA‐B*35:433 was fully characterised using sequence‐based typing after haplo‐specific amplification.
Hemizygous Amplification and Sanger Sequencing of HLA‐B*35:433 From an Umbilical‐Cord Blood Sample
HLA‐B*35:433 was fully characterised using sequence‐based typing after haplo‐specific amplification.
- Open Access
- 6 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1657-1669
Alloreactive adaptive natural killer cells in renal transplantation: Potential contribution to allograft microvascular inflammation
- 6 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1657-1669
Open AccessAlloreactive adaptive natural killer cells in renal transplantation: Potential contribution to allograft microvascular inflammation
- Open Access
NKG2C Sequence Polymorphism Modulates the Expansion of Adaptive NK Cells in Response to Human CMV
A subpopulation of NK cells with distinctive phenotype and function differentiates and expands specifically in response to infection by human cytomegalovirus (HCMV). A hallmark of these adaptive NK cells is their increased expression levels of the activating CD94/NKG2C receptor for HLA‐E, and lack of expression of its inhibitory homologue CD94/NKG2A. Their frequency is highly variable in HCMV+ individuals, and the basis for such differences is only partially understood. Here, we explore the possible influence of sequence polymorphism of the NKG2C (or KLRC2) gene on the expansion of NKG2C+NKG2A− NK cells in healthy HCMV‐seropositive donors. Our results show a significant association of greater proportions of adaptive NK cells with allele NKG2C*02. This is defined by two amino acid substitutions in comparison with the most prevalent allele, NKG2C*01, and associates with additional sequence polymorphisms in noncoding regions. Furthermore, we demonstrate consistently higher mRNA levels of NKG2C*02 in heterozygous individuals co‐expressing this allele in combination with NKG2C*01 or *03. This predominance is independent of polymorphisms in the promoter and 3′ UTRs and is appreciated also in HCMV‐seronegative donors. In summary, although additional factors are most likely implicated in the variable expansion of NKG2C+NKG2A− NK cells in response to HCMV, our results demonstrate that host immunogenetics, in particular NKG2C diversity, influences the magnitude of such response.
Open AccessNKG2C Sequence Polymorphism Modulates the Expansion of Adaptive NK Cells in Response to Human CMV
A subpopulation of NK cells with distinctive phenotype and function differentiates and expands specifically in response to infection by human cytomegalovirus (HCMV). A hallmark of these adaptive NK cells is their increased expression levels of the activating CD94/NKG2C receptor for HLA‐E, and lack of expression of its inhibitory homologue CD94/NKG2A. Their frequency is highly variable in HCMV+ individuals, and the basis for such differences is only partially understood. Here, we explore the possible influence of sequence polymorphism of the NKG2C (or KLRC2) gene on the expansion of NKG2C+NKG2A− NK cells in healthy HCMV‐seropositive donors. Our results show a significant association of greater proportions of adaptive NK cells with allele NKG2C*02. This is defined by two amino acid substitutions in comparison with the most prevalent allele, NKG2C*01, and associates with additional sequence polymorphisms in noncoding regions. Furthermore, we demonstrate consistently higher mRNA levels of NKG2C*02 in heterozygous individuals co‐expressing this allele in combination with NKG2C*01 or *03. This predominance is independent of polymorphisms in the promoter and 3′ UTRs and is appreciated also in HCMV‐seronegative donors. In summary, although additional factors are most likely implicated in the variable expansion of NKG2C+NKG2A− NK cells in response to HCMV, our results demonstrate that host immunogenetics, in particular NKG2C diversity, influences the magnitude of such response.
- 1 March 2023
- Published by IATED Academy in INTED Proceedings
- Vol. 1, 5851-5854
A PRACTICAL APPROACH TO DEFINE THE SUSTAINABILITY PROFILE OF STUDENTS: THE COMMUNITY BUILDING METHODOLOGY
- 1 March 2023
- Published by IATED Academy in INTED Proceedings
- Vol. 1, 5851-5854
A PRACTICAL APPROACH TO DEFINE THE SUSTAINABILITY PROFILE OF STUDENTS: THE COMMUNITY BUILDING METHODOLOGY
- Open Access
- 3 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (4) , 464-474
Microvascular inflammation in the absence of human leukocyte antigen-donor-specific antibody and C4d: An orphan category in Banff classification with cytotoxic T and natural killer cell infiltration
- 3 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (4) , 464-474
Open AccessMicrovascular inflammation in the absence of human leukocyte antigen-donor-specific antibody and C4d: An orphan category in Banff classification with cytotoxic T and natural killer cell infiltration
- Open Access
- 19 December 2022
- Published by Elsevier in Seminars in Immunology
- Vol. 65, 101706
Adaptive NK cell response to human cytomegalovirus: Facts and open issues
- 19 December 2022
- Published by Elsevier in Seminars in Immunology
- Vol. 65, 101706
Open AccessAdaptive NK cell response to human cytomegalovirus: Facts and open issues
- Open Access
Diversity of NKG2C genotypes in a European population: Conserved and recombinant haplotypes in the coding, promoter, and 3′‐untranslated regions
NK cells monitor altered molecular patterns in tumors and infected cells through an ample array of receptors. Two families of evolutionarily distant receptors have converged to enable human NK cells to sense levels of HLA class I ligands, frequently abnormal in altered cells. Whilst different forms of polymorphism are a hallmark of killer‐cell immunoglobulin‐like receptors and their classic HLA‐A, B, and C ligands, genetic diversity of killer‐cell lectin‐like receptors for the non‐classical HLA‐E (CD94/NKG2 heterodimers) is less conspicuous and has attracted less attention. A common pattern of diversification in both receptor families is evolution of pairs of inhibitory and activating homologs for a common ligand, the genes encoding activating receptors being more frequently affected by copy number variation (CNV). This is exemplified by the gene encoding the activating NKG2C subunit (KLRC2 or NKG2C), which marks an NK‐cell subpopulation that differentiates or expands in response to cytomegalovirus. We have studied NKG2C diversity in 240 South European individuals, using polymerase chain reaction and sequencing methods to assess both gene CNV and single‐nucleotide polymorphisms (SNPs) affecting its promoter, coding and 3′‐untranslated (3′UT) regions. Sequence analysis revealed eight common SNPs—one in the promoter, two in the coding sequence, and five in the 3′UT region. These SNPs associate strongly with each other, forming three conserved extended haplotypes (frequencies: 0.456, 0.221, and 0.117). Homo‐ and heterozygous combination of these, together with complete gene deletion (0.175) and additional haplotypes with frequencies lower than 0.015, generate a diversity of NKG2C genotypes of potential immunological importance.
Open AccessDiversity of NKG2C genotypes in a European population: Conserved and recombinant haplotypes in the coding, promoter, and 3′‐untranslated regions
NK cells monitor altered molecular patterns in tumors and infected cells through an ample array of receptors. Two families of evolutionarily distant receptors have converged to enable human NK cells to sense levels of HLA class I ligands, frequently abnormal in altered cells. Whilst different forms of polymorphism are a hallmark of killer‐cell immunoglobulin‐like receptors and their classic HLA‐A, B, and C ligands, genetic diversity of killer‐cell lectin‐like receptors for the non‐classical HLA‐E (CD94/NKG2 heterodimers) is less conspicuous and has attracted less attention. A common pattern of diversification in both receptor families is evolution of pairs of inhibitory and activating homologs for a common ligand, the genes encoding activating receptors being more frequently affected by copy number variation (CNV). This is exemplified by the gene encoding the activating NKG2C subunit (KLRC2 or NKG2C), which marks an NK‐cell subpopulation that differentiates or expands in response to cytomegalovirus. We have studied NKG2C diversity in 240 South European individuals, using polymerase chain reaction and sequencing methods to assess both gene CNV and single‐nucleotide polymorphisms (SNPs) affecting its promoter, coding and 3′‐untranslated (3′UT) regions. Sequence analysis revealed eight common SNPs—one in the promoter, two in the coding sequence, and five in the 3′UT region. These SNPs associate strongly with each other, forming three conserved extended haplotypes (frequencies: 0.456, 0.221, and 0.117). Homo‐ and heterozygous combination of these, together with complete gene deletion (0.175) and additional haplotypes with frequencies lower than 0.015, generate a diversity of NKG2C genotypes of potential immunological importance.